Discrepancies in Kappa Opioid Agonist Binding Revealed through PET Imaging.

@article{Placzek2019DiscrepanciesIK,
  title={Discrepancies in Kappa Opioid Agonist Binding Revealed through PET Imaging.},
  author={Michael S Placzek and Frederick A. Schroeder and Tao Che and Hsiao-Ying Wey and Ramesh Neelamegam and Changning Wang and Bryan L. Roth and Jacob M. Hooker},
  journal={ACS chemical neuroscience},
  year={2019},
  volume={10 1},
  pages={
          384-395
        }
}
Kappa opioid receptor (KOR) modulation has been pursued in many conceptual frameworks for the treatment of human pain, depression, and anxiety. As such, several imaging tools have been developed to characterize the density of KORs in the human brain and its occupancy by exogenous drug-like compounds. While exploring the pharmacology of KOR tool compounds using positron emission tomography (PET), we observed discrepancies in the apparent competition binding as measured by changes in binding… 
Imaging Kappa Opioid Receptors in the Living Brain with Positron Emission Tomography.
TLDR
The potential of KOR PET to detect changes in endogenous dynorphin in the human brain, to elucidate neural mechanisms and offer critical insight into disease-modifying therapeutics is discussed, and comments on other translational neuroimaging modalities such as MRI that could be used to study KOR-dynorphin tone in the living human brain are concluded.
A Survey of Molecular Imaging of Opioid Receptors
TLDR
There is scant documentation of δ-, κ-, or ORL1 receptors in healthy human brain or in neurological and psychiatric disorders; here, clinical PET research must catch up with recent progress in radiopharmaceutical chemistry.
Evaluation of Specific Binding of [11C]RTI-97 to Kappa Opioid Receptor by Autoradiography and PET Imaging in Rat.
TLDR
The overall results showed a heterogeneous repartition and specific KOR binding of [ 11C]RTI-97 in brain and a high and specific accumulation of [11C] RTI- 97 in pituitary in accordance with KOR expression.
Kappa-opioid receptors, dynorphin, and cocaine addiction: a positron emission tomography study
TLDR
Findings add to the growing evidence that pharmacotherapies targeting the KOR have the potential to significantly impact treatment development for cocaine-use disorder.
Towards in vivo imaging of functionally active 5-HT1A receptors in schizophrenia: concepts and challenges
TLDR
Imaging protocols are proposed to follow changes in the pattern of functional 5-HT 1A receptors in relation to mood deficits or cognitive processes, which could allow improved discrimination of different schizophrenia phenotypes and greater understanding of the basis of therapeutic responses to antipsychotic drugs.
Pharmacokinetic neuroimaging to study the dose-related brain kinetics and target engagement of buprenorphine in vivo
TLDR
This strategy could be further combined with pharmacodynamic exploration or pharmacological MRI to investigate the neuropharmacokinetics and neuroreceptor correlate, at least at µ-OR, of the acute effects of buprenorphine in humans.
Pleiotropic Effects of Kappa Opioid Receptor-Related Ligands in Non-human Primates.
TLDR
How non-human primates (NHP) studies facilitate the research and development of ligands targeting the KOR, effects of the endogenous opioid peptide, dynorphin A-(1-17), and its analogs in NHP, and pleiotropic effects and therapeutic applications of KOR-related ligands are highlighted.
Is There a Role for GPCR Agonist Radiotracers in PET Neuroimaging?
TLDR
All existing PET radiotracers used from animals to humans and their role for understanding the ligand-receptor paradigm of GPCR in comparison with corresponding antagonist radiot Racers are reviewed.
In Vivo Receptor Visualization and Evaluation of Receptor Occupancy with Positron Emission Tomography.
TLDR
Work in this area is reviewed, focusing on the chemical structures of reported PET tracers, their Ki/Kd values, and the physical properties relevant to target receptor selectivity, focusing especially on LogD and LogP as important physical properties that can be easily compared across a range of studies.
Radiosynthesis of [11C]LY2795050 for Preclinical and Clinical PET Imaging Using Cu(II)-Mediated Cyanation.
Copper-mediated 11C-cyanation reactions have enabled the synthesis of PET radiotracers from a range of readily available precursors and avoid the need to use more toxic Pd catalysts. In this work we
...
...

References

SHOWING 1-10 OF 65 REFERENCES
Receptor Occupancy of the κ-Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer 11C-LY2795050
TLDR
Brain penetration and KOR target engagement after single oral doses (0.5–25 mg) of LY2456302 are investigated in 13 healthy human subjects and a dose of 10 mg appears well suited for further clinical testing.
Synthesis and Evaluation of 11C-LY2795050 as a κ-Opioid Receptor Antagonist Radiotracer for PET Imaging
TLDR
This newly developed KOR antagonist tracer has since been advanced to PET imaging of KOR in humans and constitutes the first successful KOR antagonists radiotracer.
Immediate and Persistent Effects of Salvinorin A on the Kappa Opioid Receptor in Rodents, Monitored In Vivo with PET
TLDR
Data point towards an agonist-induced adaptive response by KOR, the dynamics of which have not been previously studied in vivo with PET following kappa opioid agonist administration.
Determination of the In Vivo Selectivity of a New κ-Opioid Receptor Antagonist PET Tracer 11C-LY2795050 in the Rhesus Monkey
TLDR
11C-LY2795050 is sufficiently selective for KOR over MOR in vivo to be considered an appropriate probe for studying the KOR with PET in vivo and on the basis of the finding in vivo, 88% of the PET-observed specific binding of 11C-Ly27950 50 under baseline conditions will be due to binding of the tracer at the Kor site in a region with similar prevalence of KOR and MOR.
Novel 18F-Labeled κ-Opioid Receptor Antagonist as PET Radiotracer: Synthesis and In Vivo Evaluation of 18F-LY2459989 in Nonhuman Primates
TLDR
The evaluation of 18F-LY2459989 in nonhuman primates demonstrated many attractive imaging properties: fast tissue kinetics, specific and selective binding to the KOR, and high specific binding signals.
Kinetic Modeling of 11C-LY2795050, A Novel Antagonist Radiotracer for PET Imaging of the Kappa Opioid Receptor in Humans
  • M. Naganawa, M. Zheng, Yiyun Huang
  • Biology, Medicine
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • 2014
TLDR
Binding potentials of 11C-LY2795050 can be determined if the specific binding fraction in the cerebellum is presumed to be unchanged by diseases and experimental conditions.
Structure of the human kappa opioid receptor in complex with JDTic
TLDR
Analysis of site-directed mutagenesis and ligand structure–activity relationships confirms the interactions observed in the crystal structure, thereby providing a molecular explanation for κ-OR subtype selectivity, and essential insights for the design of compounds with new pharmacological properties targeting the human λ-OR.
Medicinal Chemistry of Kappa Opioid Receptor Antagonists
TLDR
The structure–activity relationships (SAR) of nonpeptidic KOR antagonists are described and a common requirement for KOR inhibition is found: the presence of a phenol unit and a basic nitrogen.
Imaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review
  • M. Laruelle
  • Biology
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • 2000
TLDR
The results suggest that the changes in BP following changes in DA concentration might not be fully accounted by a simple occupancy model, and the data are reviewed supporting that agonist-mediated receptor internalization might play an important role in characterizing receptor-ligand interactions.
...
...